Hoffmann-la Roche Inc.

Cubist Pharmaceuticals, Incorporated

Other

Merck + Co., Inc.

International Health Management Associates, Inc.

University of Utah Research Foundation

Dennis D Keith

John F Finn

Michael Morytko

Manfred Weigele

Jason J Hill

Harry A Albrecht

Sherman Tim Waddell

Milton L Hammond

Milana M Maletic

Chung-Chen Wei

Gina M Santorelli

Aaron H Leeman

Donna Mary Huryn

Jared Silverman

Tsvetelina Ivanova Lazarova

Alan D Watson

Ian Parr

Dale Christensen

Jim Siedlecki

Yan Zhang

Siya Ram

Jan-Ji Lai

Chandrika Govardhan

Nazer Khalaf

Frederick M Konzelmann

Xian Yang Yu

John Lawson Roberts

Urvashi Hooda Dhingra

Seung-Ho Choi

Jeoung-Soo Lee

Xiang Yang Yu

Kin-Chun Thomas Luk

Ka-kong Chan

Giuseppe Federico Weber

Pamela Loreen Rossman

Paul L Gallant

Sandra O'Connor

Rudolf L Then

Philip A Wendler

Kevin F West

Frederick M Konzelman

Walter G Gowan, Jr

Roxana Yang

John P Tengi

Zhongguo Wang

The present invention provides oral formulations of poorly bioavailable and/or poorly absorbable, and/or poorly water soluble therapeutic agents. The invention features pharmaceutical composition including a biopolymer, a therapeutic agent, for example an antimicrobial agent such as ceftriaxone, and an absorption enhancer, for example a polyoxyethylene alkyl ether absorption enhancer. Methods of making and using the pharmaceutical compositions is also described.

Therapeutic compositions

The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions.

Methods for preparing purified lipopeptides

The present invention provides compositions and methods for increasing absorption of antibacterial agents, particularly third generation cephalosporin antibacterial agents, in oral dosage solid and/or suspension forms. Specifically, the composition is comprised of a biopolymer that is preferably swellable and/or mucoadhesive, a antimicrobial agent, and a cationic binding agent contained within the biopolymer such that the binding agent is ionically bound or complexed to at least one member selected from the group consisting of the biopolymer and the antimicrobial agent.

Compositions and methods for increasing the oral absorption of antimicrobials

The present invention provides compositions and methods for increasing absorption of antibacterial agents, particularly third generation cephalosporin antibacterial agents, in oral dosage solid and/or suspension forms. Specifically, the composition is comprised of a biopolymer that is preferably swellable and/or mucoadhesive, a antimicrobial agent, and a cationic binding agent contained within the biopolymer such that the binding agent is tonically bound or complexed to at least one member selected from the group consisting of the biopolymer and the antimicrobial agent.

The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.

Lipopeptides as antibacterial agents

Prolines as antimicrobial agents

Catechols as antimicrobial agents

Transfer ribonucleic acid (tRNA) synthetase inhibitors, salts, and pharmaceutically acceptable compositions thereof of the general formula:

Growing community of inventors

Montclair, NJ, United States of America

Dennis D Keith